Metformin is primarily prescribed to treat type 2 diabetes, where it lowers blood sugar by reducing the amount of glucose your liver produces. But its uses extend well beyond diabetes. Doctors also prescribe it for polycystic ovary syndrome (PCOS), prediabetes prevention, and sometimes for weight management, making it one of the most versatile medications in modern medicine.
Type 2 Diabetes
Type 2 diabetes is the FDA-approved reason metformin exists. It’s typically the first medication prescribed after a diagnosis, and for good reason: it effectively lowers blood sugar without causing the dangerous drops in blood sugar that some other diabetes drugs can trigger. Most people start on 500 mg once or twice daily, with doses gradually increased based on how well their blood sugar responds. An extended-release version, taken once daily, causes fewer digestive side effects for many people.
Beyond blood sugar control, metformin appears to protect against the complications that make diabetes dangerous. In a landmark UK study, patients with type 2 diabetes on metformin had a 20% lower risk of cardiovascular disease and a 42% lower risk of diabetes-related death compared to conventional treatment. A separate trial found that adding metformin to insulin therapy cut cardiovascular events by 40% over four years. Perhaps most striking, one large analysis found that metformin-treated diabetic patients had survival rates similar to matched non-diabetic individuals, and among those over 70, survival was actually better, despite the diabetic patients being heavier and sicker at baseline.
How Metformin Works in the Body
Metformin’s primary target is the liver. Your liver constantly produces glucose, even when you don’t need it, and metformin dials that production down. It does this by entering liver cells through a specific transporter protein and interfering with mitochondria, the energy-producing structures inside cells. Specifically, it disrupts part of the energy production chain, which shifts the cell’s energy balance and activates a master energy sensor called AMPK.
Once AMPK switches on, it triggers a cascade of helpful changes. It tells the liver to stop making glucose and stop producing fat, while ramping up fat burning instead. Over time, this makes the liver more responsive to insulin, which is the core problem in type 2 diabetes. There’s also growing evidence that metformin works partly through the gut, affecting how the intestines handle glucose and interact with gut bacteria, though these mechanisms are less well understood.
Prediabetes and Diabetes Prevention
If your blood sugar is elevated but not yet in the diabetic range, metformin can help keep it from getting worse. The Diabetes Prevention Program, a major U.S. trial, showed that metformin reduced the risk of developing type 2 diabetes by 31% compared to placebo. Lifestyle changes (diet and exercise) performed even better at 58% risk reduction, but metformin remains a practical option for people who struggle to maintain those changes long-term, particularly those under 60, those with a BMI over 35, or those with a history of gestational diabetes.
Polycystic Ovary Syndrome (PCOS)
PCOS is one of metformin’s most common off-label uses. The condition is tightly linked to insulin resistance, which drives excess production of male hormones (androgens) and disrupts ovulation. By improving insulin sensitivity, metformin can break that cycle.
In women with PCOS, metformin improves menstrual regularity, lowers androgen levels, and reduces excess hair growth. In a 14-month study, women taking metformin had more frequent menstrual cycles and less hair growth compared to placebo. The benefits are strongest in women who have insulin resistance or obesity, with more limited effects in those whose insulin levels are already normal.
For fertility specifically, metformin improves ovulation and pregnancy rates compared to placebo. Combining it with the fertility drug clomiphene produces the best results: one trial of 105 women found that the combination yielded the highest ovulation, pregnancy, and live birth rates compared to either drug alone. Metformin also appears to protect early pregnancies. Some trials have shown it significantly reduced early pregnancy loss, with miscarriage rates of around 10% in the metformin group compared to 26% to 42% in control groups. Benefits also included lower rates of preeclampsia, gestational diabetes, and preterm labor.
Weight Loss
Metformin is not a weight loss drug, but modest weight loss is a consistent side effect. A retrospective study found that patients lost an average of about 6% of their body weight at six months and 6% to 8% at twelve months, regardless of whether they had diabetes. Published studies show weight loss ranging from 0.6% to 13% of body weight, so results vary considerably from person to person. This makes metformin a useful add-on for people who need weight management alongside blood sugar control, though it’s far less potent than newer GLP-1 medications designed specifically for weight loss.
Potential Cancer-Protective Effects
A growing body of observational research links metformin use to lower cancer rates, though this hasn’t yet been confirmed in randomized trials designed to test the question directly. A large systematic review and meta-analysis published in the Journal of the National Cancer Institute found that metformin users had a 35% to 45% lower overall cancer risk compared to non-users. The strongest associations appeared for specific cancer types:
- Liver cancer: 27% to 46% lower risk across multiple study types
- Colorectal cancer: 15% to 63% lower risk depending on study design
- Bladder cancer: 30% lower risk
- Esophageal cancer: 32% lower risk
- Head and neck cancers: 42% lower risk
- Ovarian cancer: 47% lower risk
These are observational findings, meaning they show a correlation but can’t prove metformin directly prevents cancer. People who take metformin also tend to receive more regular medical monitoring, which could influence detection rates. Still, the consistency of the signal across many cancer types and study designs is notable, and one pooled analysis estimated a 31% reduction in overall cancer incidence and 34% reduction in cancer mortality among metformin users.
Aging and Longevity
Metformin’s effects across so many age-related diseases have prompted serious scientific interest in whether it could slow aging itself. In the Singapore Longitudinal Aging Study, metformin use was associated with a 51% lower risk of cognitive impairment. A small clinical trial of 58 diabetic patients with depression found that 24 weeks of metformin improved both cognitive performance and depressive symptoms. The UK Prospective Diabetes Study showed a 36% reduction in all-cause mortality in the metformin group.
These findings led to the design of the TAME (Targeting Aging with Metformin) trial, which plans to enroll 3,000 adults aged 65 to 79 across roughly 14 U.S. centers. Rather than testing metformin against any single disease, TAME will measure time to a composite outcome that includes cardiovascular events, cancer, dementia, and death. It’s the first trial ever designed to test whether a drug can slow aging as a biological process.
Vitamin B12 and Long-Term Use
One important trade-off of long-term metformin use is its effect on vitamin B12 absorption. Roughly 30% of people on long-term metformin therapy develop some degree of B12 malabsorption, and studies show that metformin can decrease serum B12 levels by 14% to 30%. B12 deficiency can cause fatigue, numbness or tingling in the hands and feet, and cognitive changes, symptoms that can be mistaken for diabetic neuropathy.
If you’ve been on metformin for several years, periodic B12 testing is worthwhile, especially if you’re older, follow a vegetarian or vegan diet, or notice new neurological symptoms. Supplementation with B12 can easily correct any deficiency.
Who Should Avoid Metformin
Metformin is cleared through the kidneys, so kidney function determines whether it’s safe to use. It can be taken safely when kidney filtration rate (eGFR) is 45 or above. Between 30 and 44, new prescriptions generally aren’t started, though someone already taking it may continue at a reduced dose with close monitoring. Below 30, metformin is contraindicated because the drug can accumulate and, in rare cases, cause a dangerous buildup of lactic acid in the blood. If you’re scheduled for a medical procedure involving contrast dye and your eGFR is below 60, metformin is typically paused the day of the procedure and for 48 hours afterward.